JP2022125941A - contact lens - Google Patents

Abstract

To provide a contact lens capable of easily nourishing the eyes with medicinal ingredients.SOLUTION: A contact lens is provided, comprising a spherical lens, to be worn on the eyeball, containing at least one medicinal component having a hydroxyl group or carboxyl group, selected from a group consisting of D-α-tocopherol, cyanocobalamin, riboflavin, and pyridoxine hydrochloride.SELECTED DRAWING: None

Description

The present invention relates to contact lenses containing pharmaceutical ingredients.

Conventionally, an egg is housed in a container provided with a shock-absorbing member against external impact, since the shell may crack due to external impact.

The number of contact lens wearers has reached 16 million, and it is widely recognized as the most familiar medical device. In the contact lens market, hydrogel contact lenses account for 70% or more of the total, and among them, daily disposable type hydrogel contact lenses have the highest share. In general, daily disposable type hydrogel contact lenses are worn for about 18 hours at the longest.

Generally, eye drops of ophthalmic drugs are not retained in the anterior segment of the eye for a long period of time and flow out with tears. For this reason, the medicinal effect is not sufficiently exerted, and in order to obtain the effect, it is necessary to apply the eyedrops several times.

It is known that the hydrogel contact lens described above takes in water molecules through hydrogen bonding and swells. At this time, it is known that the greater the ratio of hydroxyl groups and carboxyl groups present in the polymer, the more water molecules are taken in, and the water content increases.

In general, eye drops are used for eye treatment, and it is known to administer drugs to eyeballs for treatment. On the other hand, Patent Literature 1 discloses a therapeutic contact lens in which a container is provided inside the spherical surface of the contact lens to directly deliver a drug component to the eye.

Japanese Patent No. 6077127

However, the contact lens of Patent Document 1 needs to be provided with an accommodating portion, and the technique of installing the accommodating portion in the contact lens is difficult in terms of safety and cost. Furthermore, as in Patent Document 1, it is desirable that even general contact lenses, rather than contact lenses for treatment, can be easily supplied with vitamin components for relieving fatigue.

An object of the present invention is to provide a contact lens that allows easy ingestion of drug components.

(1) A contact lens in which a drug component is contained in a spherical lens worn on the eyeball.

In (1), not only therapeutic contact lenses but also general contact lenses may be used. It is desirable that the drug component, such as a vitamin component for relieving fatigue, be easily supplied from the contact lens.

(2) A contact lens according to (1), which has an anionic group having a hydroxyl group or a carboxyl group.

(3) A contact lens according to (1), wherein the drug component has a hydroxyl group or a carboxyl group.

In the contact lens of (3), specific drug components are D-α-tocopherol, cyanocobalamin, riboflavin, and pyridoxine hydrochloride.

(4) The contact lens according to (3), wherein the drug component is at least one selected from the group consisting of D-α-tocopherol, cyanocobalamin, riboflavin, and pyridoxine hydrochloride.

According to the present invention, the ophthalmic drug can be effectively and sustainedly released over a long period of time by keeping the ophthalmic drug in the anterior segment of the eye for a long period of time. be maximized.

Hereinafter, the present invention will be described in more detail using preferred embodiments. However, the following embodiments are merely examples embodying the present invention, and the present invention is not limited thereto.

TECHNICAL FIELD The present invention relates to a sustained drug release hydrogel contact lens and a drug uptake method using the same, and more particularly, it is possible to effectively and sustainedly release an ophthalmic drug having a hydroxyl group or a carboxyl group over a long period of time, The present invention relates to a sustained drug release hydrogel contact lens suitable for daily disposable contact lenses.

Hydrogel contact lenses are known to be able to prevent the adhesion of contaminants by selecting the raw materials used for the material to strengthen the hydrogen bond between the lens material and other substances and to increase the hydrophobicity.

By limiting the types of the raw materials of the hydrogel contact lens and the chemical properties of the drug component, it becomes possible to retain the medicinal component in the hydrogel contact lens for a long period of time even when the contact lens is worn. As a result, the spaces in the network structure of the hydrogel contact lens itself can be regarded as microcapsules.

A contact lens according to the present invention is a hydrogel lens having a hydroxyl group or a carboxyl group and made from 2-hydroxyethyl methacrylate. Specifically, the hydroxyl group and the carboxyl group contain 1% or more of methacrylic acid and glycerol methacrylate. In the manufacturing process of contact lenses, hydrogel contact lenses are made to contain drug components such as vitamins to manufacture contact lenses.

A method for permeating a hydrogel contact lens with a drug and gradually releasing the drug will be mainly described below.

A hydrogel contact lens becomes hydrated and swollen during the manufacturing process. A hydrated hydrogel contact lens is placed in a container containing a filling liquid to which a drug has been added, and after packing, wet heat sterilization is performed, so that the medicinal ingredient is retained in the hydrogel contact lens by high temperature and high pressure.

A phosphate buffer or a borate buffer is used as the filling liquid. This causes a pH change during eye wear, promoting release of the drug entrapped within the hydrogel contact lens.

Here, the contact lens may contain the MPC() polymer. In this case, the MPC polymer is impregnated with drugs such as vitamins. MPC polymer has twice the water absorbency of hyaluronic acid, which enhances water retention. Additionally, MPC polymers are suitable because they exclude protein components.

The contact lens is preferably a spherical lens that is worn on the eyeball and is disposable for about one day to two weeks. This is because the drug component is consumed.

Although the present invention has been described with reference to specific exemplary embodiments, the present invention is limited only by the appended claims and not by these embodiments. It will be appreciated that those skilled in the art can modify or modify these embodiments without departing from the scope and spirit of the invention.

Claims (5)

A contact lens that contains a drug component in a spherical lens worn on the eyeball. 2. The contact lens according to claim 1, which has an anionic group with a hydroxyl group or a carboxyl group. 2. The contact lens according to claim 1, wherein said drug component has a hydroxyl group or a carboxyl group. 4. The contact lens according to claim 3, wherein said drug component is at least one of the group consisting of D-[alpha]-tocopherol, cyanocobalamin, riboflavin and pyridoxine hydrochloride. 2. The contact lens according to claim 1, wherein said contact lens contains an MPC polymer and said MPC polymer is impregnated with a drug.